A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate
the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral
dose of Elacestrant.